Marvin J. Meyers, Ph.D., Ke Ding and Jing Xu
This invention relates generally to novel compositions and methods for treating malaria. It discloses that aminohydantoin compounds are inhibitors of Plasmodium aspartic proteases, such as plasmepsin II, while having reduced activity for human aspartic proteases, such as BASE and CatD. These compounds work through the aspartic protease mechanism to kill Plasmodium parasites which cause malaria. This novel mechanism of action is important for combating the rising resistance to all currently used antimalarial therapies.